

Amendments to the Claims:

Please amend claims 1, 17, 20-22 and 24, and cancel claims 2 and 6-9 without prejudice, as shown in the following listing of claims:

Listing of Claims:

1. (Currently amended) A method of reducing or eliminating neoplastic cells in an ex vivo mixture of normal, hematopoietic cells and neoplastic cells by contacting said mixture with a vesicular stomatitis virus.
 2. (canceled).
 3. (Original) A method as in claim 1 wherein said neoplastic cells are leukemia cells.
 4. (Original) A method as in claim 1 wherein said hematopoietic cells are marrow cells.
 - 5 (Original) A method as in claim 1 wherein said hematopoietic cells are peripheral blood cells.
- Claims 6-9 (canceled).
10. (Withdrawn) A method as in claim 7 wherein said non-segmented, negative sense RNA virus is a paramyxovirus.

11. (Withdrawn) A method as in claim 10 wherein said paramyxovirus is Newcastle disease virus.
12. (Withdrawn) A method as in claim 6 wherein said single-strand RNA virus is Sindbis virus.
13. (Withdrawn) A method as in claim 2 wherein said RNA virus is a double-strand RNA virus.
14. (Withdrawn) A method as in claim 13 wherein said double strand RNA virus is a reovirus.
15. (Withdrawn) A method as in claim 14 wherein said reovirus is reovirus type 3.
16. (Withdrawn) A method as in claim 13 wherein said reovirus is clonal.
17. (Currently amended) A method as in claim ~~2-1~~ wherein said ~~RNA-virus~~ is a replication-competent ~~RNA-virus~~.
18. (Withdrawn) A method as in claim 2 wherein said RNA virus is a replication-incompetent RNA virus.
19. (Original) A method as in claim 1 wherein said neoplastic cells are lymphoma cells.
20. (Currently amended) A method as in claim 1 further comprising administering a chemotherapeutic agent to the mixture before, during or after contacting with said virus.
21. (Currently amended) A method as in claim 1 further comprising administering an interferon to the mixture before, during or after contacting with said virus.

22. (Currently amended) A method of treating cancer in a mammal comprising:

- a) removing bone marrow or peripheral blood cells from said mammal,
- b) contacting said bone marrow or peripheral blood cells ex vivo with an RNA a vesicular stomatitis virus,
- c) performing myeloablative treatment on said mammal, and
- d) transplanting into said mammal the purged hematopoietic cells of step b.

23. (Original) A method as in claim 22 wherein said myeloablative treatment is high dose chemotherapy.

24. (Currently amended) A method of treating cancer in a mammal receiving a bone marrow or peripheral blood stem cell transplant comprising contacting the harvested cells of transplant cells ex vivo with a vesicular stomatitis virus, and administering the purged cells to said mammal.